Compass Therapeutics (NASDAQ:CMPX) Given Buy Rating at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a research report report published on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $32.00 target price on the stock.

Several other equities research analysts have also recently commented on the company. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price on the stock in a research note on Monday, September 16th. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $5.00 to $4.00 in a research report on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research report on Monday, November 11th. Finally, Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Compass Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $11.80.

Compass Therapeutics Stock Up 30.1 %

Shares of CMPX stock opened at $1.86 on Wednesday. The company has a market capitalization of $255.92 million, a price-to-earnings ratio of -5.03 and a beta of 0.92. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $2.68. The firm has a fifty day moving average of $1.57 and a 200-day moving average of $1.44.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. On average, equities analysts expect that Compass Therapeutics will post -0.35 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC boosted its holdings in shares of Compass Therapeutics by 195.4% during the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after acquiring an additional 112,614 shares during the period. Geode Capital Management LLC lifted its holdings in Compass Therapeutics by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after purchasing an additional 19,095 shares during the last quarter. XTX Topco Ltd bought a new stake in Compass Therapeutics in the 3rd quarter valued at $37,000. The Manufacturers Life Insurance Company acquired a new position in Compass Therapeutics in the 3rd quarter valued at $79,000. Finally, Intech Investment Management LLC bought a new position in Compass Therapeutics during the 3rd quarter worth $30,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.